nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—LTK—polycystic ovary syndrome	0.587	1	CbGaD
Crizotinib—Neuropathy—Metformin—polycystic ovary syndrome	0.000708	0.0618	CcSEcCtD
Crizotinib—Neutropenia—Metformin—polycystic ovary syndrome	0.000443	0.0386	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00044	0.0384	CcSEcCtD
Crizotinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.000422	0.0368	CcSEcCtD
Crizotinib—Infestation—Metformin—polycystic ovary syndrome	0.000422	0.0368	CcSEcCtD
Crizotinib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000414	0.0361	CcSEcCtD
Crizotinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000399	0.0348	CcSEcCtD
Crizotinib—Bradycardia—Metformin—polycystic ovary syndrome	0.000386	0.0337	CcSEcCtD
Crizotinib—EPHA2—adrenal cortex—polycystic ovary syndrome	0.000383	0.00218	CbGeAlD
Crizotinib—MERTK—adrenal gland—polycystic ovary syndrome	0.000382	0.00217	CbGeAlD
Crizotinib—MAP4K2—vagina—polycystic ovary syndrome	0.000382	0.00217	CbGeAlD
Crizotinib—TYK2—endometrium—polycystic ovary syndrome	0.000381	0.00217	CbGeAlD
Crizotinib—STK3—female gonad—polycystic ovary syndrome	0.000379	0.00215	CbGeAlD
Crizotinib—TIE1—female gonad—polycystic ovary syndrome	0.000379	0.00215	CbGeAlD
Crizotinib—FER—endocrine gland—polycystic ovary syndrome	0.000377	0.00214	CbGeAlD
Crizotinib—ALK—endocrine gland—polycystic ovary syndrome	0.000377	0.00214	CbGeAlD
Crizotinib—TYRO3—endocrine gland—polycystic ovary syndrome	0.000377	0.00214	CbGeAlD
Crizotinib—EPHA5—endocrine gland—polycystic ovary syndrome	0.000377	0.00214	CbGeAlD
Crizotinib—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000377	0.0329	CcSEcCtD
Crizotinib—STK3—vagina—polycystic ovary syndrome	0.000377	0.00214	CbGeAlD
Crizotinib—PTK2B—adipose tissue—polycystic ovary syndrome	0.000375	0.00213	CbGeAlD
Crizotinib—LYN—endocrine gland—polycystic ovary syndrome	0.000375	0.00213	CbGeAlD
Crizotinib—MAP3K3—adrenal cortex—polycystic ovary syndrome	0.000374	0.00213	CbGeAlD
Crizotinib—TEK—adrenal cortex—polycystic ovary syndrome	0.000374	0.00213	CbGeAlD
Crizotinib—RIPK2—pituitary gland—polycystic ovary syndrome	0.000374	0.00213	CbGeAlD
Crizotinib—LIMK2—adrenal gland—polycystic ovary syndrome	0.000374	0.00212	CbGeAlD
Crizotinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000373	0.0326	CcSEcCtD
Crizotinib—TNK1—endocrine gland—polycystic ovary syndrome	0.000373	0.00212	CbGeAlD
Crizotinib—NUAK2—adrenal gland—polycystic ovary syndrome	0.000372	0.00212	CbGeAlD
Crizotinib—RIPK2—adipose tissue—polycystic ovary syndrome	0.000372	0.00212	CbGeAlD
Crizotinib—MAP3K12—adrenal gland—polycystic ovary syndrome	0.00037	0.0021	CbGeAlD
Crizotinib—FLT3—adrenal gland—polycystic ovary syndrome	0.00037	0.0021	CbGeAlD
Crizotinib—ACVR1—adrenal gland—polycystic ovary syndrome	0.00037	0.0021	CbGeAlD
Crizotinib—BMPR1B—endocrine gland—polycystic ovary syndrome	0.000369	0.0021	CbGeAlD
Crizotinib—AURKA—female gonad—polycystic ovary syndrome	0.000369	0.0021	CbGeAlD
Crizotinib—RPS6KB1—endometrium—polycystic ovary syndrome	0.000369	0.0021	CbGeAlD
Crizotinib—EPHA4—uterus—polycystic ovary syndrome	0.000368	0.00209	CbGeAlD
Crizotinib—AURKA—vagina—polycystic ovary syndrome	0.000367	0.00209	CbGeAlD
Crizotinib—FGR—endometrium—polycystic ovary syndrome	0.000367	0.00208	CbGeAlD
Crizotinib—TESK1—female gonad—polycystic ovary syndrome	0.000366	0.00208	CbGeAlD
Crizotinib—AXL—endometrium—polycystic ovary syndrome	0.000365	0.00208	CbGeAlD
Crizotinib—CSF1R—embryo—polycystic ovary syndrome	0.000364	0.00207	CbGeAlD
Crizotinib—TESK1—vagina—polycystic ovary syndrome	0.000364	0.00207	CbGeAlD
Crizotinib—TNK2—endocrine gland—polycystic ovary syndrome	0.000362	0.00206	CbGeAlD
Crizotinib—IGF1R—endocrine gland—polycystic ovary syndrome	0.000362	0.00206	CbGeAlD
Crizotinib—STK35—adrenal gland—polycystic ovary syndrome	0.000362	0.00206	CbGeAlD
Crizotinib—EPHA4—pituitary gland—polycystic ovary syndrome	0.000361	0.00205	CbGeAlD
Crizotinib—MAP3K2—uterus—polycystic ovary syndrome	0.000361	0.00205	CbGeAlD
Crizotinib—EPHA4—adipose tissue—polycystic ovary syndrome	0.00036	0.00205	CbGeAlD
Crizotinib—MAP4K2—endocrine gland—polycystic ovary syndrome	0.000357	0.00203	CbGeAlD
Crizotinib—MERTK—female gonad—polycystic ovary syndrome	0.000356	0.00203	CbGeAlD
Crizotinib—Eye disorder—Metformin—polycystic ovary syndrome	0.000354	0.0309	CcSEcCtD
Crizotinib—MERTK—vagina—polycystic ovary syndrome	0.000354	0.00201	CbGeAlD
Crizotinib—PTK2—uterus—polycystic ovary syndrome	0.000353	0.00201	CbGeAlD
Crizotinib—ABL2—adrenal gland—polycystic ovary syndrome	0.000353	0.00201	CbGeAlD
Crizotinib—MAP3K2—adipose tissue—polycystic ovary syndrome	0.000353	0.00201	CbGeAlD
Crizotinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000352	0.0307	CcSEcCtD
Crizotinib—SLK—endometrium—polycystic ovary syndrome	0.000351	0.002	CbGeAlD
Crizotinib—TYK2—uterus—polycystic ovary syndrome	0.000351	0.002	CbGeAlD
Crizotinib—EPHB4—endometrium—polycystic ovary syndrome	0.000349	0.00198	CbGeAlD
Crizotinib—BMP2K—adrenal gland—polycystic ovary syndrome	0.000349	0.00198	CbGeAlD
Crizotinib—LIMK2—female gonad—polycystic ovary syndrome	0.000348	0.00198	CbGeAlD
Crizotinib—NUAK2—female gonad—polycystic ovary syndrome	0.000347	0.00197	CbGeAlD
Crizotinib—TBK1—pituitary gland—polycystic ovary syndrome	0.000347	0.00197	CbGeAlD
Crizotinib—PTK2—pituitary gland—polycystic ovary syndrome	0.000347	0.00197	CbGeAlD
Crizotinib—JAK2—endometrium—polycystic ovary syndrome	0.000347	0.00197	CbGeAlD
Crizotinib—LIMK2—vagina—polycystic ovary syndrome	0.000346	0.00197	CbGeAlD
Crizotinib—TBK1—adipose tissue—polycystic ovary syndrome	0.000346	0.00196	CbGeAlD
Crizotinib—PTK2—adipose tissue—polycystic ovary syndrome	0.000346	0.00196	CbGeAlD
Crizotinib—YES1—adrenal cortex—polycystic ovary syndrome	0.000345	0.00196	CbGeAlD
Crizotinib—NUAK2—vagina—polycystic ovary syndrome	0.000345	0.00196	CbGeAlD
Crizotinib—TYK2—pituitary gland—polycystic ovary syndrome	0.000345	0.00196	CbGeAlD
Crizotinib—MAP3K12—female gonad—polycystic ovary syndrome	0.000345	0.00196	CbGeAlD
Crizotinib—ACVR1—female gonad—polycystic ovary syndrome	0.000345	0.00196	CbGeAlD
Crizotinib—FLT3—female gonad—polycystic ovary syndrome	0.000345	0.00196	CbGeAlD
Crizotinib—AURKA—endocrine gland—polycystic ovary syndrome	0.000343	0.00195	CbGeAlD
Crizotinib—TYK2—adipose tissue—polycystic ovary syndrome	0.000343	0.00195	CbGeAlD
Crizotinib—MAP3K12—vagina—polycystic ovary syndrome	0.000343	0.00195	CbGeAlD
Crizotinib—ACVR1—vagina—polycystic ovary syndrome	0.000343	0.00195	CbGeAlD
Crizotinib—EPHA2—endometrium—polycystic ovary syndrome	0.000342	0.00195	CbGeAlD
Crizotinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000341	0.0298	CcSEcCtD
Crizotinib—TAOK3—adrenal cortex—polycystic ovary syndrome	0.000341	0.00194	CbGeAlD
Crizotinib—TESK1—endocrine gland—polycystic ovary syndrome	0.000341	0.00194	CbGeAlD
Crizotinib—IRAK1—adipose tissue—polycystic ovary syndrome	0.000339	0.00193	CbGeAlD
Crizotinib—LCK—uterus—polycystic ovary syndrome	0.000338	0.00192	CbGeAlD
Crizotinib—STK35—female gonad—polycystic ovary syndrome	0.000338	0.00192	CbGeAlD
Crizotinib—PTK2B—adrenal gland—polycystic ovary syndrome	0.000337	0.00191	CbGeAlD
Crizotinib—AXL—uterus—polycystic ovary syndrome	0.000336	0.00191	CbGeAlD
Crizotinib—STK35—vagina—polycystic ovary syndrome	0.000336	0.00191	CbGeAlD
Crizotinib—MAP3K3—endometrium—polycystic ovary syndrome	0.000334	0.0019	CbGeAlD
Crizotinib—MAP4K5—endometrium—polycystic ovary syndrome	0.000334	0.0019	CbGeAlD
Crizotinib—TEK—endometrium—polycystic ovary syndrome	0.000334	0.0019	CbGeAlD
Crizotinib—RIPK2—adrenal gland—polycystic ovary syndrome	0.000334	0.0019	CbGeAlD
Crizotinib—RPS6KB1—pituitary gland—polycystic ovary syndrome	0.000334	0.0019	CbGeAlD
Crizotinib—RPS6KB1—adipose tissue—polycystic ovary syndrome	0.000332	0.00189	CbGeAlD
Crizotinib—FGR—pituitary gland—polycystic ovary syndrome	0.000332	0.00189	CbGeAlD
Crizotinib—MERTK—endocrine gland—polycystic ovary syndrome	0.000331	0.00188	CbGeAlD
Crizotinib—AXL—pituitary gland—polycystic ovary syndrome	0.00033	0.00188	CbGeAlD
Crizotinib—FGR—adipose tissue—polycystic ovary syndrome	0.00033	0.00188	CbGeAlD
Crizotinib—LCK—adipose tissue—polycystic ovary syndrome	0.00033	0.00188	CbGeAlD
Crizotinib—Malnutrition—Metformin—polycystic ovary syndrome	0.00033	0.0288	CcSEcCtD
Crizotinib—AXL—adipose tissue—polycystic ovary syndrome	0.000329	0.00187	CbGeAlD
Crizotinib—ABL2—female gonad—polycystic ovary syndrome	0.000329	0.00187	CbGeAlD
Crizotinib—ABL2—vagina—polycystic ovary syndrome	0.000327	0.00186	CbGeAlD
Crizotinib—BMP2K—female gonad—polycystic ovary syndrome	0.000325	0.00185	CbGeAlD
Crizotinib—LIMK2—endocrine gland—polycystic ovary syndrome	0.000324	0.00184	CbGeAlD
Crizotinib—SLK—uterus—polycystic ovary syndrome	0.000324	0.00184	CbGeAlD
Crizotinib—BMP2K—vagina—polycystic ovary syndrome	0.000323	0.00184	CbGeAlD
Crizotinib—Dysgeusia—Metformin—polycystic ovary syndrome	0.000323	0.0282	CcSEcCtD
Crizotinib—EPHA4—adrenal gland—polycystic ovary syndrome	0.000323	0.00184	CbGeAlD
Crizotinib—EPHB4—uterus—polycystic ovary syndrome	0.000322	0.00183	CbGeAlD
Crizotinib—MAP3K12—endocrine gland—polycystic ovary syndrome	0.000321	0.00182	CbGeAlD
Crizotinib—ACVR1—endocrine gland—polycystic ovary syndrome	0.000321	0.00182	CbGeAlD
Crizotinib—FLT3—endocrine gland—polycystic ovary syndrome	0.000321	0.00182	CbGeAlD
Crizotinib—EPHB6—endometrium—polycystic ovary syndrome	0.000319	0.00181	CbGeAlD
Crizotinib—SLK—pituitary gland—polycystic ovary syndrome	0.000318	0.00181	CbGeAlD
Crizotinib—SLK—adipose tissue—polycystic ovary syndrome	0.000317	0.0018	CbGeAlD
Crizotinib—MAP3K2—adrenal gland—polycystic ovary syndrome	0.000317	0.0018	CbGeAlD
Crizotinib—EPHB4—pituitary gland—polycystic ovary syndrome	0.000316	0.0018	CbGeAlD
Crizotinib—EPHB4—adipose tissue—polycystic ovary syndrome	0.000315	0.00179	CbGeAlD
Crizotinib—STK35—endocrine gland—polycystic ovary syndrome	0.000314	0.00179	CbGeAlD
Crizotinib—PTK2B—female gonad—polycystic ovary syndrome	0.000314	0.00178	CbGeAlD
Crizotinib—JAK2—pituitary gland—polycystic ovary syndrome	0.000314	0.00178	CbGeAlD
Crizotinib—JAK2—adipose tissue—polycystic ovary syndrome	0.000312	0.00178	CbGeAlD
Crizotinib—PTK2B—vagina—polycystic ovary syndrome	0.000312	0.00177	CbGeAlD
Crizotinib—RIPK2—female gonad—polycystic ovary syndrome	0.000311	0.00177	CbGeAlD
Crizotinib—Vision blurred—Metformin—polycystic ovary syndrome	0.000311	0.0271	CcSEcCtD
Crizotinib—TBK1—adrenal gland—polycystic ovary syndrome	0.00031	0.00176	CbGeAlD
Crizotinib—PTK2—adrenal gland—polycystic ovary syndrome	0.00031	0.00176	CbGeAlD
Crizotinib—EPHA2—pituitary gland—polycystic ovary syndrome	0.00031	0.00176	CbGeAlD
Crizotinib—RIPK2—vagina—polycystic ovary syndrome	0.000309	0.00176	CbGeAlD
Crizotinib—EPHA2—adipose tissue—polycystic ovary syndrome	0.000309	0.00175	CbGeAlD
Crizotinib—YES1—endometrium—polycystic ovary syndrome	0.000308	0.00175	CbGeAlD
Crizotinib—TYK2—adrenal gland—polycystic ovary syndrome	0.000308	0.00175	CbGeAlD
Crizotinib—MAP4K5—uterus—polycystic ovary syndrome	0.000308	0.00175	CbGeAlD
Crizotinib—TEK—uterus—polycystic ovary syndrome	0.000308	0.00175	CbGeAlD
Crizotinib—TAOK3—endometrium—polycystic ovary syndrome	0.000304	0.00173	CbGeAlD
Crizotinib—IRAK1—adrenal gland—polycystic ovary syndrome	0.000304	0.00173	CbGeAlD
Crizotinib—BMP2K—endocrine gland—polycystic ovary syndrome	0.000302	0.00172	CbGeAlD
Crizotinib—TEK—pituitary gland—polycystic ovary syndrome	0.000302	0.00172	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—polycystic ovary syndrome	0.000302	0.00172	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—polycystic ovary syndrome	0.000302	0.00172	CbGeAlD
Crizotinib—TEK—adipose tissue—polycystic ovary syndrome	0.000301	0.00171	CbGeAlD
Crizotinib—MAP3K3—adipose tissue—polycystic ovary syndrome	0.000301	0.00171	CbGeAlD
Crizotinib—MAP4K5—adipose tissue—polycystic ovary syndrome	0.000301	0.00171	CbGeAlD
Crizotinib—EPHA4—female gonad—polycystic ovary syndrome	0.000301	0.00171	CbGeAlD
Crizotinib—EPHA4—vagina—polycystic ovary syndrome	0.000299	0.0017	CbGeAlD
Crizotinib—CSF1R—adrenal cortex—polycystic ovary syndrome	0.000298	0.0017	CbGeAlD
Crizotinib—RPS6KB1—adrenal gland—polycystic ovary syndrome	0.000298	0.0017	CbGeAlD
Crizotinib—FGR—adrenal gland—polycystic ovary syndrome	0.000296	0.00169	CbGeAlD
Crizotinib—LCK—adrenal gland—polycystic ovary syndrome	0.000296	0.00169	CbGeAlD
Crizotinib—Syncope—Metformin—polycystic ovary syndrome	0.000296	0.0258	CcSEcCtD
Crizotinib—AXL—adrenal gland—polycystic ovary syndrome	0.000295	0.00168	CbGeAlD
Crizotinib—MAP3K2—female gonad—polycystic ovary syndrome	0.000295	0.00168	CbGeAlD
Crizotinib—PTK2B—endocrine gland—polycystic ovary syndrome	0.000292	0.00166	CbGeAlD
Crizotinib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00029	0.0253	CcSEcCtD
Crizotinib—RIPK2—endocrine gland—polycystic ovary syndrome	0.00029	0.00165	CbGeAlD
Crizotinib—PTK2—female gonad—polycystic ovary syndrome	0.000289	0.00164	CbGeAlD
Crizotinib—TBK1—female gonad—polycystic ovary syndrome	0.000289	0.00164	CbGeAlD
Crizotinib—EPHB6—pituitary gland—polycystic ovary syndrome	0.000289	0.00164	CbGeAlD
Crizotinib—ABL1—embryo—polycystic ovary syndrome	0.000288	0.00164	CbGeAlD
Crizotinib—EPHB6—adipose tissue—polycystic ovary syndrome	0.000288	0.00164	CbGeAlD
Crizotinib—TBK1—vagina—polycystic ovary syndrome	0.000287	0.00163	CbGeAlD
Crizotinib—PTK2—vagina—polycystic ovary syndrome	0.000287	0.00163	CbGeAlD
Crizotinib—TYK2—female gonad—polycystic ovary syndrome	0.000287	0.00163	CbGeAlD
Crizotinib—TYK2—vagina—polycystic ovary syndrome	0.000285	0.00162	CbGeAlD
Crizotinib—YES1—uterus—polycystic ovary syndrome	0.000284	0.00162	CbGeAlD
Crizotinib—SLK—adrenal gland—polycystic ovary syndrome	0.000284	0.00162	CbGeAlD
Crizotinib—IRAK1—female gonad—polycystic ovary syndrome	0.000283	0.00161	CbGeAlD
Crizotinib—EPHB4—adrenal gland—polycystic ovary syndrome	0.000282	0.0016	CbGeAlD
Crizotinib—STK10—uterus—polycystic ovary syndrome	0.000282	0.0016	CbGeAlD
Crizotinib—TAOK3—uterus—polycystic ovary syndrome	0.000281	0.0016	CbGeAlD
Crizotinib—JAK2—adrenal gland—polycystic ovary syndrome	0.00028	0.00159	CbGeAlD
Crizotinib—EPHA4—endocrine gland—polycystic ovary syndrome	0.00028	0.00159	CbGeAlD
Crizotinib—YES1—pituitary gland—polycystic ovary syndrome	0.000279	0.00159	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000279	0.0243	CcSEcCtD
Crizotinib—RPS6KB1—female gonad—polycystic ovary syndrome	0.000278	0.00158	CbGeAlD
Crizotinib—YES1—adipose tissue—polycystic ovary syndrome	0.000278	0.00158	CbGeAlD
Crizotinib—EPHA2—adrenal gland—polycystic ovary syndrome	0.000277	0.00157	CbGeAlD
Crizotinib—RPS6KB1—vagina—polycystic ovary syndrome	0.000276	0.00157	CbGeAlD
Crizotinib—FGR—female gonad—polycystic ovary syndrome	0.000276	0.00157	CbGeAlD
Crizotinib—LCK—female gonad—polycystic ovary syndrome	0.000276	0.00157	CbGeAlD
Crizotinib—TAOK3—pituitary gland—polycystic ovary syndrome	0.000276	0.00157	CbGeAlD
Crizotinib—STK10—adipose tissue—polycystic ovary syndrome	0.000275	0.00157	CbGeAlD
Crizotinib—AXL—female gonad—polycystic ovary syndrome	0.000275	0.00157	CbGeAlD
Crizotinib—LCK—vagina—polycystic ovary syndrome	0.000275	0.00156	CbGeAlD
Crizotinib—FGR—vagina—polycystic ovary syndrome	0.000275	0.00156	CbGeAlD
Crizotinib—MAP3K2—endocrine gland—polycystic ovary syndrome	0.000274	0.00156	CbGeAlD
Crizotinib—TAOK3—adipose tissue—polycystic ovary syndrome	0.000274	0.00156	CbGeAlD
Crizotinib—AXL—vagina—polycystic ovary syndrome	0.000274	0.00156	CbGeAlD
Crizotinib—TEK—adrenal gland—polycystic ovary syndrome	0.00027	0.00154	CbGeAlD
Crizotinib—MAP3K3—adrenal gland—polycystic ovary syndrome	0.00027	0.00154	CbGeAlD
Crizotinib—MAP4K5—adrenal gland—polycystic ovary syndrome	0.00027	0.00154	CbGeAlD
Crizotinib—Oedema—Metformin—polycystic ovary syndrome	0.000269	0.0235	CcSEcCtD
Crizotinib—TBK1—endocrine gland—polycystic ovary syndrome	0.000269	0.00153	CbGeAlD
Crizotinib—PTK2—endocrine gland—polycystic ovary syndrome	0.000269	0.00153	CbGeAlD
Crizotinib—SRC—adipose tissue—polycystic ovary syndrome	0.000267	0.00152	CbGeAlD
Crizotinib—Infection—Metformin—polycystic ovary syndrome	0.000267	0.0233	CcSEcCtD
Crizotinib—TYK2—endocrine gland—polycystic ovary syndrome	0.000267	0.00152	CbGeAlD
Crizotinib—CSF1R—endometrium—polycystic ovary syndrome	0.000266	0.00151	CbGeAlD
Crizotinib—SLK—female gonad—polycystic ovary syndrome	0.000265	0.00151	CbGeAlD
Crizotinib—Shock—Metformin—polycystic ovary syndrome	0.000265	0.0231	CcSEcCtD
Crizotinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000264	0.023	CcSEcCtD
Crizotinib—SLK—vagina—polycystic ovary syndrome	0.000263	0.0015	CbGeAlD
Crizotinib—EPHB4—female gonad—polycystic ovary syndrome	0.000263	0.0015	CbGeAlD
Crizotinib—EPHB4—vagina—polycystic ovary syndrome	0.000261	0.00149	CbGeAlD
Crizotinib—Skin disorder—Metformin—polycystic ovary syndrome	0.000261	0.0228	CcSEcCtD
Crizotinib—JAK2—female gonad—polycystic ovary syndrome	0.000261	0.00149	CbGeAlD
Crizotinib—JAK2—vagina—polycystic ovary syndrome	0.00026	0.00148	CbGeAlD
Crizotinib—RPS6KB1—endocrine gland—polycystic ovary syndrome	0.000259	0.00147	CbGeAlD
Crizotinib—EPHA2—female gonad—polycystic ovary syndrome	0.000258	0.00147	CbGeAlD
Crizotinib—EPHB6—adrenal gland—polycystic ovary syndrome	0.000258	0.00147	CbGeAlD
Crizotinib—FGR—endocrine gland—polycystic ovary syndrome	0.000257	0.00146	CbGeAlD
Crizotinib—EPHA2—vagina—polycystic ovary syndrome	0.000256	0.00146	CbGeAlD
Crizotinib—AXL—endocrine gland—polycystic ovary syndrome	0.000256	0.00146	CbGeAlD
Crizotinib—TEK—female gonad—polycystic ovary syndrome	0.000252	0.00143	CbGeAlD
Crizotinib—MAP4K5—female gonad—polycystic ovary syndrome	0.000252	0.00143	CbGeAlD
Crizotinib—MAP3K3—female gonad—polycystic ovary syndrome	0.000252	0.00143	CbGeAlD
Crizotinib—MAP4K5—vagina—polycystic ovary syndrome	0.00025	0.00142	CbGeAlD
Crizotinib—MAP3K3—vagina—polycystic ovary syndrome	0.00025	0.00142	CbGeAlD
Crizotinib—YES1—adrenal gland—polycystic ovary syndrome	0.000249	0.00142	CbGeAlD
Crizotinib—STK10—adrenal gland—polycystic ovary syndrome	0.000247	0.0014	CbGeAlD
Crizotinib—TAOK3—adrenal gland—polycystic ovary syndrome	0.000246	0.0014	CbGeAlD
Crizotinib—CSF1R—uterus—polycystic ovary syndrome	0.000245	0.0014	CbGeAlD
Crizotinib—EPHB4—endocrine gland—polycystic ovary syndrome	0.000245	0.00139	CbGeAlD
Crizotinib—JAK2—endocrine gland—polycystic ovary syndrome	0.000243	0.00138	CbGeAlD
Crizotinib—Paraesthesia—Metformin—polycystic ovary syndrome	0.000242	0.0211	CcSEcCtD
Crizotinib—CSF1R—pituitary gland—polycystic ovary syndrome	0.000241	0.00137	CbGeAlD
Crizotinib—EPHB6—female gonad—polycystic ovary syndrome	0.000241	0.00137	CbGeAlD
Crizotinib—CSF1R—adipose tissue—polycystic ovary syndrome	0.00024	0.00137	CbGeAlD
Crizotinib—EPHA2—endocrine gland—polycystic ovary syndrome	0.00024	0.00136	CbGeAlD
Crizotinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.00024	0.0209	CcSEcCtD
Crizotinib—SRC—adrenal gland—polycystic ovary syndrome	0.00024	0.00136	CbGeAlD
Crizotinib—EPHB6—vagina—polycystic ovary syndrome	0.000239	0.00136	CbGeAlD
Crizotinib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000237	0.0207	CcSEcCtD
Crizotinib—ABL1—adrenal cortex—polycystic ovary syndrome	0.000236	0.00134	CbGeAlD
Crizotinib—TEK—endocrine gland—polycystic ovary syndrome	0.000234	0.00133	CbGeAlD
Crizotinib—MAP3K3—endocrine gland—polycystic ovary syndrome	0.000234	0.00133	CbGeAlD
Crizotinib—MAP4K5—endocrine gland—polycystic ovary syndrome	0.000234	0.00133	CbGeAlD
Crizotinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000234	0.0204	CcSEcCtD
Crizotinib—YES1—female gonad—polycystic ovary syndrome	0.000232	0.00132	CbGeAlD
Crizotinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000232	0.0203	CcSEcCtD
Crizotinib—Fatigue—Metformin—polycystic ovary syndrome	0.000232	0.0203	CcSEcCtD
Crizotinib—YES1—vagina—polycystic ovary syndrome	0.000231	0.00131	CbGeAlD
Crizotinib—STK10—female gonad—polycystic ovary syndrome	0.00023	0.00131	CbGeAlD
Crizotinib—Constipation—Metformin—polycystic ovary syndrome	0.00023	0.0201	CcSEcCtD
Crizotinib—TAOK3—female gonad—polycystic ovary syndrome	0.00023	0.00131	CbGeAlD
Crizotinib—STK10—vagina—polycystic ovary syndrome	0.000229	0.0013	CbGeAlD
Crizotinib—TAOK3—vagina—polycystic ovary syndrome	0.000228	0.0013	CbGeAlD
Crizotinib—SRC—female gonad—polycystic ovary syndrome	0.000224	0.00127	CbGeAlD
Crizotinib—YES1—endocrine gland—polycystic ovary syndrome	0.000216	0.00123	CbGeAlD
Crizotinib—CSF1R—adrenal gland—polycystic ovary syndrome	0.000215	0.00122	CbGeAlD
Crizotinib—STK10—endocrine gland—polycystic ovary syndrome	0.000214	0.00122	CbGeAlD
Crizotinib—TAOK3—endocrine gland—polycystic ovary syndrome	0.000213	0.00121	CbGeAlD
Crizotinib—ABL1—endometrium—polycystic ovary syndrome	0.000211	0.0012	CbGeAlD
Crizotinib—SRC—endocrine gland—polycystic ovary syndrome	0.000208	0.00118	CbGeAlD
Crizotinib—CSF1R—female gonad—polycystic ovary syndrome	0.000201	0.00114	CbGeAlD
Crizotinib—CSF1R—vagina—polycystic ovary syndrome	0.0002	0.00113	CbGeAlD
Crizotinib—ABL1—uterus—polycystic ovary syndrome	0.000194	0.0011	CbGeAlD
Crizotinib—Asthenia—Metformin—polycystic ovary syndrome	0.000193	0.0169	CcSEcCtD
Crizotinib—ABL1—pituitary gland—polycystic ovary syndrome	0.000191	0.00108	CbGeAlD
Crizotinib—ABL1—adipose tissue—polycystic ovary syndrome	0.00019	0.00108	CbGeAlD
Crizotinib—CSF1R—endocrine gland—polycystic ovary syndrome	0.000187	0.00106	CbGeAlD
Crizotinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000184	0.0161	CcSEcCtD
Crizotinib—Dizziness—Metformin—polycystic ovary syndrome	0.000178	0.0155	CcSEcCtD
Crizotinib—Vomiting—Metformin—polycystic ovary syndrome	0.000171	0.0149	CcSEcCtD
Crizotinib—ABL1—adrenal gland—polycystic ovary syndrome	0.00017	0.000968	CbGeAlD
Crizotinib—Rash—Metformin—polycystic ovary syndrome	0.00017	0.0148	CcSEcCtD
Crizotinib—Dermatitis—Metformin—polycystic ovary syndrome	0.00017	0.0148	CcSEcCtD
Crizotinib—Nausea—Metformin—polycystic ovary syndrome	0.00016	0.014	CcSEcCtD
Crizotinib—ABL1—female gonad—polycystic ovary syndrome	0.000159	0.000903	CbGeAlD
Crizotinib—ABL1—vagina—polycystic ovary syndrome	0.000158	0.000897	CbGeAlD
Crizotinib—ABL1—endocrine gland—polycystic ovary syndrome	0.000148	0.000839	CbGeAlD
Crizotinib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000111	0.000632	CbGeAlD
Crizotinib—CYP3A5—female gonad—polycystic ovary syndrome	9.29e-05	0.000528	CbGeAlD
Crizotinib—CYP3A5—vagina—polycystic ovary syndrome	9.23e-05	0.000525	CbGeAlD
Crizotinib—ABCB1—embryo—polycystic ovary syndrome	8.95e-05	0.000509	CbGeAlD
Crizotinib—CYP3A5—endocrine gland—polycystic ovary syndrome	8.64e-05	0.000491	CbGeAlD
Crizotinib—ABCB1—adrenal cortex—polycystic ovary syndrome	7.33e-05	0.000417	CbGeAlD
Crizotinib—ABCB1—endometrium—polycystic ovary syndrome	6.55e-05	0.000372	CbGeAlD
Crizotinib—CYP3A4—endocrine gland—polycystic ovary syndrome	6.48e-05	0.000369	CbGeAlD
Crizotinib—ABCB1—uterus—polycystic ovary syndrome	6.03e-05	0.000343	CbGeAlD
Crizotinib—ABCB1—pituitary gland—polycystic ovary syndrome	5.93e-05	0.000337	CbGeAlD
Crizotinib—ABCB1—adipose tissue—polycystic ovary syndrome	5.9e-05	0.000336	CbGeAlD
Crizotinib—ABCB1—adrenal gland—polycystic ovary syndrome	5.29e-05	0.000301	CbGeAlD
Crizotinib—ABCB1—female gonad—polycystic ovary syndrome	4.94e-05	0.000281	CbGeAlD
Crizotinib—ABCB1—vagina—polycystic ovary syndrome	4.91e-05	0.000279	CbGeAlD
Crizotinib—ABCB1—endocrine gland—polycystic ovary syndrome	4.59e-05	0.000261	CbGeAlD
Crizotinib—LCK—Hemostasis—VEGFA—polycystic ovary syndrome	2.75e-06	1.22e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.74e-06	1.21e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ATF1—polycystic ovary syndrome	2.74e-06	1.21e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PGR—polycystic ovary syndrome	2.73e-06	1.21e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IRS2—polycystic ovary syndrome	2.73e-06	1.21e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CRP—polycystic ovary syndrome	2.73e-06	1.21e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LHB—polycystic ovary syndrome	2.72e-06	1.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IRS1—polycystic ovary syndrome	2.72e-06	1.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.71e-06	1.2e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.7e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT2—polycystic ovary syndrome	2.69e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—GNAS—polycystic ovary syndrome	2.69e-06	1.19e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—LEP—polycystic ovary syndrome	2.68e-06	1.19e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT2—polycystic ovary syndrome	2.68e-06	1.18e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IL6—polycystic ovary syndrome	2.67e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.67e-06	1.18e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	2.66e-06	1.18e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.66e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—IL6—polycystic ovary syndrome	2.65e-06	1.18e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—IL6—polycystic ovary syndrome	2.65e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NCOR1—polycystic ovary syndrome	2.65e-06	1.17e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTHFR—polycystic ovary syndrome	2.65e-06	1.17e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	2.63e-06	1.16e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.62e-06	1.16e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL6—polycystic ovary syndrome	2.61e-06	1.16e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NRG1—polycystic ovary syndrome	2.6e-06	1.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—LEP—polycystic ovary syndrome	2.6e-06	1.15e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	2.59e-06	1.15e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL6—polycystic ovary syndrome	2.59e-06	1.14e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IL6—polycystic ovary syndrome	2.58e-06	1.14e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	2.58e-06	1.14e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.56e-06	1.13e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.55e-06	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PLAT—polycystic ovary syndrome	2.54e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GHRL—polycystic ovary syndrome	2.54e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NGFR—polycystic ovary syndrome	2.52e-06	1.12e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.52e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IRS2—polycystic ovary syndrome	2.52e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT2—polycystic ovary syndrome	2.52e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.51e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRG1—polycystic ovary syndrome	2.51e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—IRS1—polycystic ovary syndrome	2.51e-06	1.11e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—polycystic ovary syndrome	2.5e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PRL—polycystic ovary syndrome	2.5e-06	1.11e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—polycystic ovary syndrome	2.48e-06	1.1e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—POMC—polycystic ovary syndrome	2.46e-06	1.09e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—INS—polycystic ovary syndrome	2.44e-06	1.08e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—polycystic ovary syndrome	2.43e-06	1.08e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—POMC—polycystic ovary syndrome	2.42e-06	1.07e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ATF1—polycystic ovary syndrome	2.42e-06	1.07e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IRS2—polycystic ovary syndrome	2.41e-06	1.07e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CRP—polycystic ovary syndrome	2.41e-06	1.07e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—INS—polycystic ovary syndrome	2.41e-06	1.07e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—INS—polycystic ovary syndrome	2.4e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—polycystic ovary syndrome	2.4e-06	1.06e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.39e-06	1.06e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	2.39e-06	1.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.39e-06	1.06e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IRS1—polycystic ovary syndrome	2.38e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.37e-06	1.05e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	2.37e-06	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.36e-06	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.36e-06	1.05e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—polycystic ovary syndrome	2.36e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—polycystic ovary syndrome	2.36e-06	1.05e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.36e-06	1.05e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	2.35e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRG1—polycystic ovary syndrome	2.35e-06	1.04e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—BCL2—polycystic ovary syndrome	2.35e-06	1.04e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTHFR—polycystic ovary syndrome	2.34e-06	1.04e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—BCL2—polycystic ovary syndrome	2.34e-06	1.03e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—polycystic ovary syndrome	2.34e-06	1.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.33e-06	1.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.33e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT2—polycystic ovary syndrome	2.32e-06	1.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.32e-06	1.03e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—POMC—polycystic ovary syndrome	2.3e-06	1.02e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	2.3e-06	1.02e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—INS—polycystic ovary syndrome	2.29e-06	1.01e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	2.27e-06	1e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.25e-06	9.94e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TH—polycystic ovary syndrome	2.24e-06	9.91e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NGFR—polycystic ovary syndrome	2.23e-06	9.9e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—POMC—polycystic ovary syndrome	2.23e-06	9.89e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IRS2—polycystic ovary syndrome	2.23e-06	9.87e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—INS—polycystic ovary syndrome	2.22e-06	9.83e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRL—polycystic ovary syndrome	2.21e-06	9.81e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.21e-06	9.81e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	2.21e-06	9.8e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.21e-06	9.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—polycystic ovary syndrome	2.21e-06	9.79e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.21e-06	9.79e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.21e-06	9.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—SERPINE1—polycystic ovary syndrome	2.21e-06	9.77e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT2—polycystic ovary syndrome	2.2e-06	9.76e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	2.2e-06	9.75e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IRS1—polycystic ovary syndrome	2.2e-06	9.73e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—BCL2—polycystic ovary syndrome	2.2e-06	9.73e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	2.18e-06	9.64e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	2.16e-06	9.57e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IRS2—polycystic ovary syndrome	2.15e-06	9.52e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.15e-06	9.51e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.15e-06	9.5e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	2.13e-06	9.41e-06	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—polycystic ovary syndrome	2.11e-06	9.36e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IRS1—polycystic ovary syndrome	2.11e-06	9.33e-06	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—polycystic ovary syndrome	2.11e-06	9.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—LEP—polycystic ovary syndrome	2.1e-06	9.32e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—INS—polycystic ovary syndrome	2.1e-06	9.32e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.1e-06	9.3e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.1e-06	9.3e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	2.1e-06	9.3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.1e-06	9.28e-06	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—polycystic ovary syndrome	2.09e-06	9.24e-06	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	2.08e-06	9.19e-06	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—polycystic ovary syndrome	2.08e-06	9.19e-06	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—polycystic ovary syndrome	2.07e-06	9.16e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	2.06e-06	9.11e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	2.05e-06	9.06e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.04e-06	9.03e-06	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—polycystic ovary syndrome	2.04e-06	9.02e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT2—polycystic ovary syndrome	2.03e-06	9.01e-06	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—polycystic ovary syndrome	2.03e-06	8.97e-06	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—polycystic ovary syndrome	2.02e-06	8.94e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.01e-06	8.91e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.98e-06	8.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—LEP—polycystic ovary syndrome	1.97e-06	8.72e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.97e-06	8.72e-06	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—polycystic ovary syndrome	1.95e-06	8.64e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.95e-06	8.64e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT2—polycystic ovary syndrome	1.95e-06	8.64e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GNAS—polycystic ovary syndrome	1.95e-06	8.63e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IRS1—polycystic ovary syndrome	1.95e-06	8.61e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.94e-06	8.59e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—SERPINE1—polycystic ovary syndrome	1.93e-06	8.56e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.93e-06	8.53e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—BCL2—polycystic ovary syndrome	1.92e-06	8.52e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IRS1—polycystic ovary syndrome	1.88e-06	8.31e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—INS—polycystic ovary syndrome	1.86e-06	8.25e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.86e-06	8.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.86e-06	8.22e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1.84e-06	8.14e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	1.83e-06	8.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRG1—polycystic ovary syndrome	1.82e-06	8.07e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—polycystic ovary syndrome	1.81e-06	8.01e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT2—polycystic ovary syndrome	1.8e-06	7.97e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.8e-06	7.97e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—INS—polycystic ovary syndrome	1.8e-06	7.96e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	1.76e-06	7.81e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.76e-06	7.78e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	1.74e-06	7.71e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1—polycystic ovary syndrome	1.74e-06	7.7e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT2—polycystic ovary syndrome	1.74e-06	7.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	1.73e-06	7.64e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—polycystic ovary syndrome	1.71e-06	7.59e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—SERPINE1—polycystic ovary syndrome	1.71e-06	7.58e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	1.71e-06	7.57e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—BCL2—polycystic ovary syndrome	1.7e-06	7.54e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—polycystic ovary syndrome	1.69e-06	7.49e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	1.69e-06	7.48e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—INS—polycystic ovary syndrome	1.68e-06	7.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.68e-06	7.42e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—polycystic ovary syndrome	1.65e-06	7.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.65e-06	7.31e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	1.65e-06	7.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	1.64e-06	7.27e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.64e-06	7.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.64e-06	7.25e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—polycystic ovary syndrome	1.63e-06	7.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.63e-06	7.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.63e-06	7.2e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.59e-06	7.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS2—polycystic ovary syndrome	1.56e-06	6.91e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—polycystic ovary syndrome	1.55e-06	6.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.55e-06	6.84e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.54e-06	6.84e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	1.54e-06	6.84e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	1.54e-06	6.81e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	1.54e-06	6.81e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—polycystic ovary syndrome	1.53e-06	6.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LEP—polycystic ovary syndrome	1.53e-06	6.76e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.52e-06	6.75e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—polycystic ovary syndrome	1.51e-06	6.7e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—polycystic ovary syndrome	1.5e-06	6.64e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	1.48e-06	6.56e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	1.47e-06	6.53e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.46e-06	6.47e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.44e-06	6.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	1.43e-06	6.31e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	1.42e-06	6.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.41e-06	6.26e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.4e-06	6.21e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—polycystic ovary syndrome	1.39e-06	6.13e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	1.38e-06	6.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.36e-06	6.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS1—polycystic ovary syndrome	1.36e-06	6.03e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—polycystic ovary syndrome	1.36e-06	6.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.35e-06	5.99e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.34e-06	5.94e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	1.31e-06	5.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—polycystic ovary syndrome	1.31e-06	5.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.31e-06	5.8e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—polycystic ovary syndrome	1.3e-06	5.78e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.29e-06	5.73e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—polycystic ovary syndrome	1.28e-06	5.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—polycystic ovary syndrome	1.26e-06	5.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT2—polycystic ovary syndrome	1.26e-06	5.58e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	1.25e-06	5.52e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—polycystic ovary syndrome	1.25e-06	5.51e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	1.24e-06	5.51e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.24e-06	5.51e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	1.23e-06	5.45e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	1.22e-06	5.42e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.22e-06	5.41e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—polycystic ovary syndrome	1.22e-06	5.38e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—polycystic ovary syndrome	1.21e-06	5.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.2e-06	5.32e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.2e-06	5.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.16e-06	5.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—polycystic ovary syndrome	1.14e-06	5.04e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.14e-06	5.03e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—polycystic ovary syndrome	1.07e-06	4.73e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.06e-06	4.71e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—polycystic ovary syndrome	1.05e-06	4.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—polycystic ovary syndrome	1.05e-06	4.65e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.04e-06	4.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.01e-06	4.48e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—polycystic ovary syndrome	9.99e-07	4.42e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—polycystic ovary syndrome	9.96e-07	4.41e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—polycystic ovary syndrome	9.7e-07	4.3e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	9.52e-07	4.21e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	9.41e-07	4.17e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.31e-07	4.12e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	9.28e-07	4.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	9.23e-07	4.09e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—polycystic ovary syndrome	9.2e-07	4.07e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—polycystic ovary syndrome	8.82e-07	3.9e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	8.49e-07	3.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.24e-07	3.65e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—polycystic ovary syndrome	8.14e-07	3.6e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	8.09e-07	3.58e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—polycystic ovary syndrome	7.86e-07	3.48e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	7.67e-07	3.4e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—polycystic ovary syndrome	7.35e-07	3.26e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	7.15e-07	3.17e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	6.44e-07	2.85e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	5.8e-07	2.57e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	5.72e-07	2.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—polycystic ovary syndrome	5.7e-07	2.52e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	5.69e-07	2.52e-06	CbGpPWpGaD
